Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration. Ukr. j. ophthalmol. [інтернет]. 02, Липень 2024 [цит. за 09, Серпень 2026];(3):28-32. доступний у: https://ua.ozhurnal.com/index.php/files/article/view/130